MX2020010653A - Anticuerpo anti-muerte programada-ligando 1 y su uso. - Google Patents
Anticuerpo anti-muerte programada-ligando 1 y su uso.Info
- Publication number
- MX2020010653A MX2020010653A MX2020010653A MX2020010653A MX2020010653A MX 2020010653 A MX2020010653 A MX 2020010653A MX 2020010653 A MX2020010653 A MX 2020010653A MX 2020010653 A MX2020010653 A MX 2020010653A MX 2020010653 A MX2020010653 A MX 2020010653A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- sub
- antibody
- bispecific antibody
- antigen
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 6
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 4
- GQSAIMYKDAPIDJ-UHFFFAOYSA-N 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-5-ol Chemical class O1CCC2OC(O)CC21 GQSAIMYKDAPIDJ-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- -1 amine compounds Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 abstract 1
- 229960005107 darunavir Drugs 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000006911 enzymatic reaction Methods 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
- 238000006476 reductive cyclization reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan un anticuerpo que se une a la proteína PD-L1 o a la proteína CD137, un fragmento de unión al antígeno o una variante de la misma, así como un anticuerpo biespecífico que puede unirse tanto a la proteína PD-L1 como a la proteína CD137; el anticuerpo biespecífico tiene una gran capacidad para reconocer específicamente la proteína PD-L1 y la proteína CD137, y puede mejorar la actividad de las células T; también se proporciona el uso del anticuerpo o el fragmento de unión al antígeno o la variante del mismo y el anticuerpo biespecífico en la prevención y el tratamiento de tumores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810309302 | 2018-04-09 | ||
| PCT/CN2018/102584 WO2019196309A1 (zh) | 2018-04-09 | 2018-08-27 | 抗pd-l1抗体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010653A true MX2020010653A (es) | 2020-10-28 |
Family
ID=68163043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010653A MX2020010653A (es) | 2018-04-09 | 2018-08-27 | Anticuerpo anti-muerte programada-ligando 1 y su uso. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3778635A4 (es) |
| JP (2) | JP7360720B2 (es) |
| KR (1) | KR20200140882A (es) |
| CN (4) | CN113121698B (es) |
| AU (1) | AU2018418224A1 (es) |
| BR (1) | BR112020020637A2 (es) |
| CA (1) | CA3095498A1 (es) |
| CL (1) | CL2020002600A1 (es) |
| CO (1) | CO2020013833A2 (es) |
| EA (1) | EA202092420A1 (es) |
| IL (2) | IL297847B2 (es) |
| MX (1) | MX2020010653A (es) |
| PH (1) | PH12020551661A1 (es) |
| SG (1) | SG11202009791VA (es) |
| WO (1) | WO2019196309A1 (es) |
| ZA (1) | ZA202006255B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022087458A1 (en) * | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| US20240034801A1 (en) * | 2021-01-08 | 2024-02-01 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| WO2023000675A1 (zh) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程（集团）股份有限公司 | 靶向pd-l1和4-1bb的双特异性抗体 |
| WO2023134657A1 (zh) * | 2022-01-11 | 2023-07-20 | 原启生物科技(上海)有限责任公司 | 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途 |
| WO2023138638A1 (zh) * | 2022-01-24 | 2023-07-27 | 原启生物科技(上海)有限责任公司 | 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途 |
| CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| BR112015007672A2 (pt) * | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| TW201613635A (en) * | 2014-02-04 | 2016-04-16 | Pfizer | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| CN105017421B (zh) * | 2014-04-16 | 2017-12-26 | 中国人民解放军海军总医院 | 一种抗her2双特异性抗体及其制备方法与应用 |
| JP6909153B2 (ja) * | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗ｐｄ−ｌ１抗体 |
| CN105669862A (zh) * | 2014-11-21 | 2016-06-15 | 上海中信国健药业股份有限公司 | 抗人pd-l1/kir双特异性抗体及其制备方法和应用 |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| EA037855B1 (ru) * | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 |
| CA3027209C (en) * | 2016-06-13 | 2022-08-16 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| BR112019005895A2 (pt) * | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| CN106699891B (zh) * | 2017-01-25 | 2019-04-09 | 北京天广实生物技术股份有限公司 | 一种抗pd-l1抗体、其药物组合物及其用途 |
| CN107298713B (zh) * | 2017-08-15 | 2019-12-06 | 联合益康（北京）生物科技有限公司 | 一种抗pd-l1抗体及应用、制备方法、试剂盒和药物 |
-
2018
- 2018-08-27 CN CN202110431887.XA patent/CN113121698B/zh active Active
- 2018-08-27 IL IL297847A patent/IL297847B2/en unknown
- 2018-08-27 JP JP2020554903A patent/JP7360720B2/ja active Active
- 2018-08-27 SG SG11202009791VA patent/SG11202009791VA/en unknown
- 2018-08-27 EA EA202092420A patent/EA202092420A1/ru unknown
- 2018-08-27 BR BR112020020637-7A patent/BR112020020637A2/pt unknown
- 2018-08-27 CN CN202211353129.1A patent/CN115991778A/zh active Pending
- 2018-08-27 AU AU2018418224A patent/AU2018418224A1/en active Pending
- 2018-08-27 EP EP18914556.8A patent/EP3778635A4/en active Pending
- 2018-08-27 CN CN201880044363.1A patent/CN110869390B/zh active Active
- 2018-08-27 KR KR1020207032204A patent/KR20200140882A/ko not_active Application Discontinuation
- 2018-08-27 MX MX2020010653A patent/MX2020010653A/es unknown
- 2018-08-27 CA CA3095498A patent/CA3095498A1/en active Pending
- 2018-08-27 WO PCT/CN2018/102584 patent/WO2019196309A1/zh unknown
- 2018-08-27 CN CN202110430146.XA patent/CN113087799B/zh active Active
-
2020
- 2020-10-07 PH PH12020551661A patent/PH12020551661A1/en unknown
- 2020-10-08 IL IL277893A patent/IL277893A/en unknown
- 2020-10-08 ZA ZA2020/06255A patent/ZA202006255B/en unknown
- 2020-10-08 CL CL2020002600A patent/CL2020002600A1/es unknown
- 2020-11-05 CO CONC2020/0013833A patent/CO2020013833A2/es unknown
-
2023
- 2023-09-25 JP JP2023160978A patent/JP2023179558A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3778635A4 (en) | 2022-01-26 |
| IL297847A (en) | 2023-01-01 |
| CO2020013833A2 (es) | 2020-12-21 |
| CN110869390B (zh) | 2021-05-11 |
| CL2020002600A1 (es) | 2021-01-29 |
| IL277893A (en) | 2020-11-30 |
| IL297847B2 (en) | 2024-02-01 |
| CA3095498A1 (en) | 2019-10-17 |
| SG11202009791VA (en) | 2020-11-27 |
| KR20200140882A (ko) | 2020-12-16 |
| CN113087799A (zh) | 2021-07-09 |
| CN113087799B (zh) | 2023-03-31 |
| AU2018418224A1 (en) | 2020-11-26 |
| IL297847B1 (en) | 2023-10-01 |
| CN113121698B (zh) | 2022-11-01 |
| EA202092420A1 (ru) | 2021-01-28 |
| CN115991778A (zh) | 2023-04-21 |
| JP2023179558A (ja) | 2023-12-19 |
| CN113121698A (zh) | 2021-07-16 |
| US20210380698A1 (en) | 2021-12-09 |
| JP2021530430A (ja) | 2021-11-11 |
| CN110869390A (zh) | 2020-03-06 |
| PH12020551661A1 (en) | 2021-06-07 |
| BR112020020637A2 (pt) | 2021-03-23 |
| ZA202006255B (en) | 2022-03-30 |
| EP3778635A1 (en) | 2021-02-17 |
| WO2019196309A1 (zh) | 2019-10-17 |
| JP7360720B2 (ja) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010653A (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso. | |
| Charan et al. | Haliclonacyclamines A and B, cytotoxic alkaloids from the tropical marine sponge Haliclona sp | |
| Brenneman et al. | Enantioselective synthesis of (+)-anatoxin-a via enyne metathesis | |
| NZ534374A (en) | Method of synthesizing camptothecin-relating compounds | |
| Peng et al. | Prenylated indole diketopiperazines from the marine-derived fungus Aspergillus versicolor | |
| NO20074222L (no) | Fremgangsmater for fremstilling av ansamitosiner | |
| NO20071866L (no) | Prosesser for beskyttelse av optisk aktive aminderivater | |
| WO2005086735A3 (en) | Novel bicyclic compounds as modulators of androgen receptor function and method | |
| WO2005113536A3 (en) | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | |
| Hu et al. | A study on the substituent effects of norbornadiene derivatives in iridium-catalyzed asymmetric [2+ 2] cycloaddition reactions | |
| de Meijere et al. | Mono‐and Disubstituted N, N‐Dialkylcyclopropylamines from Dialkylformamides via Ligand‐Exchanged Titanium–Alkene Complexes | |
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
| Kaga et al. | Synthesis of tricyclic marine alkaloids, cylindricines, lepadiformines, fasicularin, and polycitorols: a recent update | |
| NZ600800A (en) | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | |
| ZA202212150B (en) | Tricyclic compounds as egfr inhibitors | |
| Wascholowski et al. | A general organocatalytic enantioselective nitrocyclopropanation reaction | |
| Zheng et al. | SmI2-mediated radical coupling strategy to securinega alkaloids: Total synthesis of (−)-14, 15-Dihydrosecurinine and formal total synthesis of (−)-securinine | |
| Koviach et al. | An in situ iminium formation-allylation approach towards the 1-aza-[4.5. 0]-spirobicyclic core of halichlorine and pinnaic acid | |
| Rossen et al. | Mechanistic studies on the diastereoselective halohydroxylation of γ-δ unsaturated carboxamides | |
| MX2018010128A (es) | Toxina nueva y metodo de preparacion de un intermediario de la misma. | |
| MX2021014319A (es) | Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo. | |
| Yamashita et al. | Syntheses of (±)-9-epi-hederacine A and (±)-9-epi-hederacine B | |
| SG195224A1 (en) | Method for producing optically active #-substituted proline | |
| WO2007109786A3 (en) | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones |